Hengrui Bags World-First Approval for Anti-PD-(L)1/TGF-β Agent In China

 
• By Dexter Jie Yan
  
first line treatment
Hengrui's relafupu-α (SHR-1701) is leading the PD-(L)1/TGF-β drug class worldwide. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip